Fremanezumab for the Prevention of Menstrually-related Migraine Attacks - a Prospective, Observational Study According to Routine Neurological Care in Switzerland
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Fremanezumab (Primary)
- Indications Menstrual migraine; Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- Acronyms FROMM
- 29 Oct 2024 New trial record